Research led by the Steno Diabetes Center Odense shows that high levels of interleukin (IL)-6 predicted increased risk for obesity-related cancer in newly diagnosed people with type 2 diabetes. Notably, other markers of inflammation, tumor necrosis factor-alpha (TNF-alpha) and high sensitivity C-reactive protein (hsCRP), did not significantly predict cancer risk…

There is a team readily available to report 24/7 to a facility at the University of Chicago Medical Center to quickly receive and process a deceased donor’s pancreas into isolated islets for infusion into a patient with type 1 diabetes. The results have been astounding. Some patients who underwent allogeneic…

A large Danish study led by Odense University suggests women who experience gestational diabetes are not at increased risk of breast cancer compared with the general population. Although gestational diabetes resolves after birth, women who have had the condition are known to be at higher risk of developing type 2…

Analyzing PET/CT scans using deep learning algorithms to evaluate images can help identify people at risk of developing type 2 diabetes, according to a study published today in the journal Radiology. The study of more than 32,000 people over the age of 25 in Korea, highlights the value of so-called…

Research led by Helmholtz Munich in Germany showed COVID-19 infection in high-risk young people almost doubled the rate of progression to type 1 diabetes during the pandemic compared with those who were not infected with the virus. The pandemic showed that COVID-19 increased the risk of diabetes. A systemic review…

A study of more than 1.5 million people with type 2 diabetes has shown that individuals using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have a significantly lower risk for obesity-associated cancers (OACs) than those using insulin. The findings “provide preliminary evidence of the potential benefit of GLP-1 RAs for cancer…

While semaglutide has been in the biopharma limelight for its impressive effects on weight loss in adults with and without type 2 diabetes, it looks like it could soon be playing second fiddle to another glucagon-like peptide 1 GLP-1 receptor agonist-based medication when it comes to weight loss. A study…

Two separate Phase III clinical trials have shown that the diabetes and obesity drug tirzepatide led to significant decreases in the in the number of breathing interruptions during sleep of patients with obstructive sleep apnea (OSA), setting it up as potentially the first medication to treat the disorder. The results…

A study of more than 8,000 gut microbiome profiles sampled from people in eight different countries led by researchers based at Harvard University shows abnormal changes in 19 bacterial species are linked to increased risk of developing type 2 diabetes. Of the 19 gut bacteria species identified, five were linked…

Promising new data from a trial of Vertex’s early phase islet cell therapy VX-880 for type 1 diabetes (T1D) trial showed three patients, with 12 months of follow-up, reached insulin independence. All of the dozen patients in the trial showed improvement over all—they received the full dose of VX-880 and…

Social determinants of health such as food insecurity, low household income and a lack of health insurance has been linked to youth-onset of prediabetes—higher-than-normal blood sugar—in adolescents, independent of race and ethnicity according to a new study published today in JAMA Open Network. The research, by investigators at the University…

Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist designed to treat type 2 diabetes, is also effective at improving cardiovascular and kidney health and reducing the risk for death in people with type 2 diabetes and kidney disease. As reported in the New England Journal of Medicine, the patients randomized…

Researchers at City of Hope have discovered new biomarkers that could predict kidney failure in patients with type 1 diabetes (T1D), according to a study published today in Science Translational Medicine. The study, led by Rama Natarajan, PhD, deputy director of the Arthur Riggs Diabetes & Metabolism Research Institute at…

Scientists at the Harvard Pilgrim Health Care Institute have made a breakthrough in understanding the development of gestational diabetes (GDM), focusing on the placenta’s role in the condition that affects approximately 14 percent of pregnancies worldwide. The study, titled “Placental IGFBP1 levels during early pregnancy and the risk of insulin…

A new position statement published today in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism states that diabetes care is more effective when the patient experience is taken into account when formulating a treatment plan. This approach, which moves beyond simply taking into account the clinical numbers and focusing…